Sleeplay’s Post

🚨 BREAKING NEWS 🚨 Eli Lilly and Company has achieved a groundbreaking milestone with the FDA's approval of Zepbound (tirzepatide), the first prescription medication specifically designed for adults facing moderate-to-severe obstructive sleep apnea (OSA) alongside obesity. 🌟 This innovative treatment offers hope to millions, as clinical trials revealed participants experienced an average weight loss of up to 20% and a significant reduction in sleep interruptions. Nearly half reported remission or substantial improvement in OSA symptoms after just one year! 💡 Key Highlights: - Zepbound shows a fivefold increase in effectiveness over placebo for reducing nightly breathing disruptions. - Combination therapy with positive airway pressure (PAP) enhances OSA symptom relief. - Addresses both weight reduction and OSA symptoms, improving overall quality of life. As obesity rates rise, Zepbound's dual-action mechanism presents a vital tool for healthcare providers tackling these intertwined challenges. This approval not only marks an advancement in treatment options but also highlights Eli Lilly’s commitment to innovation in health care. 🔗 Click the link to learn more about this transformative development! #EliLilly #FDAApproval #General #HealthcareInnovation #ObstructiveSleepApnea #SleepMedicine #WeightLoss #Zepbound #MarketAccess #MarketAccessToday

The FDA recently announced the approval of Zepbound (tirzepatide) for Obstructive Sleep Apnea (OSA). This milestone highlights the far-reaching benefits of GLP-1 and GLP-1/GIP therapies—not only for weight loss but also for addressing comorbidities like OSA that impact health and drive healthcare costs. Science-based obesity care involves more than helping patients lose weight. It can also prevent or improve weight-related comorbidities, delivering significant value to employers and payers. Is your organization seeking a partner to deliver science-based obesity care that helps patients achieve sustained weight loss and improved health while controlling cost? Contact us at employers@formhealth.co to learn how we can help.

Most would rally around intensive therapeutic lifestyle change, if and only if, MACE criteria were a primary endpoint and the results benefitted in larger controlled studies. In my opinion more work needs to be done to determine GLP-1 dosing, duration, and short/long-term safety and efficacy.

Eli Lilly and Company has revealed results from the SURMOUNT-OSA #Phase3 #clinicaltrials where #tirzepatide demonstrated to lower the severity of moderate-to-severe #obstructivesleepapnea (OSA) in obese adults irrespective of positive airway pressure (PAP) therapy status. Results were presented at the American Diabetes Association's 84th Scientific Sessions. Tirzepatide met all primary and key secondary endpoints. An approval decision for tirzepatide to treat #OSA and #obesity will be expected by the end of the year. #ADASciSessions 

Eli Lilly and Company just added to the long list of potential health benefits of its popular weight loss drug, Zepbound. The weekly injection showed the potential to treat patients with obstructive sleep apnea and obesity in two late-stage clinical trials, according to the company. For some patients, #Zepbound reduced breathing issues during sleep by up to 63%. That effect could make a huge difference for the estimated 80 million Americans with the common breathing disorder. So, what's next? The #pharma giant said it plans to present the results at an upcoming medical conference and submit it to the FDA and regulators in other countries in mid-2024. More details in my latest at CNBC: https://lnkd.in/gw2fHT2T #obesitydrug #weightloss #sleepapnea #elililly

GLP-1s Just one more extra benefit. Whether or not GLP-1s ultimately pass the long term testing for weight loss, unlike previous attempts at pharmacuetical based weight loss attempts, GLP-1s are demonstrating to potentially have positive effects on other health conditions which could keep GLP-1s around even if they fail the long term weight loss test. So ignoring their presence might not be the best strategy. Remember, they are locked in as the drug of choice for diabetes treatment. https://lnkd.in/gT4kkFnh

Eli Lilly's recent announcement reveals compelling results from their latest study on tirzepatide, showing a significant reduction in the severity of obstructive sleep apnea (OSA) among adults with obesity—a mean reduction of 63% in the apnea-hypopnea index (AHI). This finding raises an essential question: Does tirzepatide directly impact OSA, or is the effect primarily mediated through weight loss? Understanding this distinction is crucial as adherence to CPAP, the standard treatment, remains a challenge for many patients. In addition to analyzing clinical trial data, generating real-world evidence from recent claims data could provide deeper insights into tirzepatide’s mechanisms. This approach would help clarify its broader implications for health policy and treatment strategies, potentially offering a dual-benefit treatment strategy for patients struggling with both obesity and OSA. I look forward to discussing how these innovations might enhance patient outcomes and healthcare efficiencies. Insights from colleagues and experts at Eli Lilly are particularly welcome as we consider the future of OSA treatment. https://lnkd.in/ebirPYJW #tirzepatide #Zepbound #Mounjaro #OSA #obesity Eli Lilly and Company Gregory Daniel Haijun Tian Christian Nguyen Kristina Boye Boye Mark

The landscape of OSA care is evolving, and innovation has never been more critical. In a recent MedCity News article, our CEO, Lawrence Miller MD, shares insights on the urgent need for diverse treatment options to address the complexity of this chronic disease affecting 80 million people in the US and nearly 1 billion globally. At Apnimed, we’re leading this charge with AD109, a once-nightly oral therapy currently in Phase 3 trials. Designed to target the neuromuscular dysfunction that underlies OSA, AD109 has the potential to become the first pharmacological treatment for this condition, offering new hope for patients who need accessible, effective options. Learn more about how Apnimed is driving innovation and shaping the future of OSA care: https://lnkd.in/gKTTPCRD #OSA #Innovation #PatientCentricity #AD109 #HealthcareInnovation

It’s the obesity. I applaud this indication but I’m curious how far we can take this. What if we demonstrate reduction in rates of obesity related cancers? I love how these drugs continue to further the link between obesity and chronic conditions. Will the cost of therapy be offset by the gains? #healthcare #health #obesity #FDA

Eli Lilly announced the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity. #Zepbound #ExpandingApplications #OSA #EliLilly